Annual vaccination is the best prevention of influenza. However, the immunogenicity of
influenza vaccines varies among different populations. It is important to fully identify the …

With an increase in the global burden of cancer-related deaths, the quest for developing
new therapeutic solutions has taken momentum. In this regard, the idea of using cancer …

Influenza A virus (IAV) infection represents a global health challenge. Excavating antiviral
active components from traditional Chinese medicine (TCM) is a promising anti-IAV strategy …

Background Influenza is a highly contagious respiratory disease which poses a serious
threat to public health globally, causing severe diseases in 3-5 million humans and resulting …

Influenza A viruses (IAVs) have a main natural reservoir in wild birds. IAVs are highly
contagious, continually evolve, and have a wide host range that includes various …

Influenza poses a huge threat to global public health. Influenza vaccines are the most
effective and cost-effective means to control influenza. Current influenza vaccines mainly …

There is an urgent need to improve protective responses to influenza vaccination in the
elderly population, which is at especially high risk for adverse outcomes from influenza …

Summary Background The Sanofi/GSK AS03-adjuvanted (VidPrevtyn Beta) vaccine and the
Pfizer-BioNTech mRNA (Comirnaty Original/Omicron BA. 4-5) bivalent vaccine were offered …

Influenza virus, a highly mutable respiratory pathogen, causes significant disease nearly
every year. Current vaccines are designed to protect against circulating influenza strains of a …

The threat of viral influenza infections has sparked research efforts to develop vaccines that
can induce broadly protective immunity with safe adjuvants that trigger robust immune …